NX-019

· Nalo Therapeutics Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NX-019, covering 2025-03-11 to 2025-03-11. Get the full timeline:

Most recent: Clinical Trial Update: A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer [Phase 1]